• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher

    3/4/24 2:34:26 PM ET
    $BCDA
    $BIVI
    $CRDF
    $DECK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCDA alert in real time by email

    U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday.

    The Dow traded down 0.20% to 39,007.30 while the NASDAQ fell 0.18% to 16,245.77. The S&P 500 also fell, dropping, 0.01% to 5,137.05.

    Check This Out: Top 4 Tech Stocks That May Implode This Month

     

    Leading and Lagging Sectors

     

    Utilities shares rose by 0.9% on Monday.

    In trading on Monday, communication services shares fell by 1.6%.

     

    Top Headline

     

    Super Micro Computer, Inc. (NASDAQ:SMCI) will join the S&P 500 Index, effective March 18, S&P Dow Jones Indices, a division of S&P Global, said in a release. Deckers Outdoor Corporation (NASDAQ:DECK) will replace Zions Bancorporation (NASDAQ:ZION) in the S&P 500.

     

    Equities Trading UP

     

    Cardiff Oncology, Inc. (NASDAQ:CRDF) shares shot up 16% to $3.3862 after the company reported better-than-expected fourth-quarter financial results, provided a clinical update on the Phase 2 randomized second-line ONSEMBLE trial in patients with RAS-mutated mCRC and announced the first patient was dosed in the randomized first-line RAS-mutated mCRC trial.

    Shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) got a boost, surging 23% to $3.4550 after the company announced FDA clearance to recruit teen subjects into both of its ongoing Netherton Syndrome clinical studies.

    Renalytix Plc (NASDAQ:RNLX) shares were also up, gaining 27% to $1.3250 after the company announced that it received an unsolicited approach from a publicly listed strategic diagnostics company.

     

    Equities Trading DOWN

     

    BioVie Inc. (NASDAQ:BIVI) shares dropped 43% to $1.0850 after the company reported pricing of public offering.

    Shares of BioCardia, Inc. (NASDAQ:BCDA) were down 21% to $0.4599 after reporting interim results from Phase III CardiAMP cell therapy heart failure trial.

    JOANN Inc. (NASDAQ:JOAN) was down, falling 42% to $0.2937 following a Bloomberg report stating the company is contemplating a bankruptcy filing to restructure its debt and regain financial stability.

    Also Check This Out: 'I Think You've Got An Interesting Stock Here': Cramer On This Advertising Company

     

    Commodities

     

    In commodity news, oil traded down 1.5% to $78.72 while gold traded up 1.5% at $2,126.00.

    Silver traded rose 2.7% to $23.99 on Monday while copper fell 0.2% to $3.8530.

     

    Euro zone

     

    European shares closed mostly lower today. The eurozone’s STOXX 600 fell 0.03%, London’s FTSE 100 fell 0.55% while Spain’s IBEX 35 Index rose 0.05% The German DAX declined 0.11% French CAC 40 rose 0.28% while Italy’s FTSE MIB Index fell 0.07%.

    The number of people registering as jobless in Spain declined by 0.3% to 2.76 million in February.

     

    Asia Pacific Markets

     

    Asian markets closed higher on Monday, with Japan’s Nikkei 225 gaining 0.50%, Hong Kong’s Hang Seng Index climbing 0.04%, China’s Shanghai Composite Index gaining 0.41% and India’s S&P BSE Sensex gaining 0.2%.

    Singapore’s manufacturing PMI slipped to 50.6 in February from 50.7 in the prior month.

     

    Economics

     

    No economic report of significance is due for Monday.

    Now Read This: How To Earn $500 A Month From Nordstrom Stock Ahead Of Q4 Earnings Report

    Get the next $BCDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCDA
    $BIVI
    $CRDF
    $DECK

    CompanyDatePrice TargetRatingAnalyst
    Deckers Outdoor Corporation
    $DECK
    2/20/2026Hold → Buy
    Argus
    Zions Bancorporation N.A.
    $ZION
    2/9/2026$65.00Outperform → Neutral
    Robert W. Baird
    Deckers Outdoor Corporation
    $DECK
    1/30/2026$105.00 → $120.00Market Perform
    Telsey Advisory Group
    Deckers Outdoor Corporation
    $DECK
    1/14/2026$102.00Hold
    Jefferies
    Super Micro Computer Inc.
    $SMCI
    1/13/2026$26.00Sell
    Goldman
    Deckers Outdoor Corporation
    $DECK
    1/7/2026$85.00Neutral → Underweight
    Piper Sandler
    Deckers Outdoor Corporation
    $DECK
    1/7/2026$125.00Outperform → Neutral
    Robert W. Baird
    Cardiff Oncology Inc.
    $CRDF
    1/5/2026$12.00Outperform
    Noble Capital Markets
    More analyst ratings

    $BCDA
    $BIVI
    $CRDF
    $DECK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deckers Outdoor upgraded by Argus

    Argus upgraded Deckers Outdoor from Hold to Buy

    2/20/26 8:19:35 AM ET
    $DECK
    Shoe Manufacturing
    Consumer Discretionary

    Zions Bancorp downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Zions Bancorp from Outperform to Neutral and set a new price target of $65.00

    2/9/26 7:00:44 AM ET
    $ZION
    Major Banks
    Finance

    Telsey Advisory Group reiterated coverage on Deckers Outdoor with a new price target

    Telsey Advisory Group reiterated coverage of Deckers Outdoor with a rating of Market Perform and set a new price target of $120.00 from $105.00 previously

    1/30/26 6:49:41 AM ET
    $DECK
    Shoe Manufacturing
    Consumer Discretionary

    $BCDA
    $BIVI
    $CRDF
    $DECK
    SEC Filings

    View All

    SEC Form 144 filed by Zions Bancorporation N.A.

    144 - ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ (0000109380) (Subject)

    2/18/26 1:59:07 PM ET
    $ZION
    Major Banks
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by Quoin Pharmaceuticals Ltd.

    SCHEDULE 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    2/11/26 5:10:41 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form 13F-HR filed by Zions Bancorporation N.A.

    13F-HR - ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ (0000109380) (Filer)

    2/11/26 3:08:27 PM ET
    $ZION
    Major Banks
    Finance

    $BCDA
    $BIVI
    $CRDF
    $DECK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,444 worth of shares (1,100 units at $1.31), increasing direct ownership by 0.41% to 267,966 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    12/17/25 6:32:43 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    $BIVI
    $CRDF
    $DECK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Smith Jennifer Anne exercised 2,089 shares at a strike of $52.90 and sold $130,521 worth of shares (2,089 units at $62.48) (SEC Form 4)

    4 - ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ (0000109380) (Issuer)

    2/19/26 4:39:01 PM ET
    $ZION
    Major Banks
    Finance

    Director Liaw Yih-Shyan Wally converted options into 3,400 shares and covered exercise/tax liability with 1,220 shares, increasing direct ownership by 2% to 94,492 units (SEC Form 4)

    4 - Super Micro Computer, Inc. (0001375365) (Issuer)

    2/19/26 4:27:31 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    SVP, Chief Accounting Officer Cheung Kenneth converted options into 2,250 shares and covered exercise/tax liability with 927 shares, increasing direct ownership by 2% to 58,530 units (SEC Form 4)

    4 - Super Micro Computer, Inc. (0001375365) (Issuer)

    2/19/26 4:26:52 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    $BCDA
    $BIVI
    $CRDF
    $DECK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Join Biovie's Exclusive Live Investor Webinar and Q&A Session on March 4

    CARSON CITY, Nev., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on March 4, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss BioVie's investigational drug candidate bezisterim (NE3107), a first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer's, Parkinson's, and Long COVID, where it has shown encouraging signals of improved cogniti

    2/23/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZIONS BANCORPORATION RECEIVES 15 COALITION GREENWICH BEST BANK AWARDS FOR 2026

    SALT LAKE CITY, Feb. 20, 2026 /PRNewswire/ -- Zions Bancorporation, N.A. (NASDAQ:ZION) is pleased to announce that it has been recognized by Coalition Greenwich as a 2026 Best Bank Award winner, receiving 15 Best Bank Awards for serving middle market and small business clients. Since the start of the awards in 2009, Zions is one of only four U.S. banks to have averaged 15 or more middle market and small business Coalition Greenwich Best Bank Awards annually and has received the second highest number of awards in the middle market category. These awards are based on approximately

    2/20/26 10:23:00 AM ET
    $ZION
    Major Banks
    Finance

    Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25-26, 2026. Details of the presentation can be found below. Presenter: Mani Mohindru, PhD (Interim CEO) Date: 02/25/2026Time: 1:20 PM ET Interested parties can register for and access the live webcast for the conference by visiting the "Events" section of the Cardiff Oncology website. The

    2/19/26 7:00:00 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    $BIVI
    $CRDF
    $DECK
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

    SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served as Vice President of Quality and Regulatory. Prior to that, he served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical (a blood glucose monitoring device company), and as Dir

    11/24/25 8:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vectra Bank Colorado welcomes Dominic Karaba as its next President & CEO

    Vectra Bank Welcomes New Local Leadership DENVER, Nov. 10, 2025 /PRNewswire/ -- Vectra Bank Colorado is proud to announce the appointment of Dominic Karaba as its next President and CEO. Karaba succeeds Bruce Alexander, who will retire after a 25-year career at Vectra Bank. This transition marks an exciting chapter for Vectra Bank, as Vectra continues its commitment to local leadership, community engagement, and pro-active relationship banking. Karaba brings a wealth of experience to Vectra Bank, having served in senior executive roles in Commercial and Business banking in Col

    11/10/25 2:43:00 PM ET
    $ZION
    Major Banks
    Finance

    $BCDA
    $BIVI
    $CRDF
    $DECK
    Financials

    Live finance-specific insights

    View All

    Supermicro Announces Second Quarter Fiscal Year 2026 Financial Results

    Super Micro Computer, Inc. (NASDAQ:SMCI) ("Supermicro" or the "Company"), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, today announced unaudited financial results for its second quarter of fiscal year 2026 ended December 31, 2025. Second Quarter Fiscal Year 2026 Highlights Net sales of $12.7 billion versus $5.0 billion in Q1'26 and $5.7 billion in Q2'25 Gross margin of 6.3% versus 9.3% in Q1'26 and 11.8% in Q2'25 Net income of $401 million versus $168 million in Q1'26 and $321 million in Q2'25 Diluted net income per common share of $0.60 versus $0.26 in Q1'26 and $0.51 in Q2'25 Non-GAAP gross margin of 6.4% versus 11.9% in Q2'25 Non-GAAP diluted net

    2/3/26 4:51:00 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    ZIONS BANCORPORATION'S BOARD ANNOUNCES APPROVAL OF SHARE REPURCHASE AND DECLARES DIVIDENDS ON COMMON AND PREFERRED STOCK

    SALT LAKE CITY, Jan. 30, 2026 /PRNewswire/ -- Zions Bancorporation, N.A. (NASDAQ:ZION) announced today that its board of directors ("board") has authorized a share repurchase of up to $75 million of the company's common stock for the first quarter of 2026. The timing and amount of any such action will depend on market conditions, regulatory requirements, and other factors or uncertainties and may be updated at the discretion of the board. The board also declared a regular quarterly dividend of $0.45 per common share, payable February 19, 2026, to shareholders of record at the

    1/30/26 2:01:00 PM ET
    $ZION
    Major Banks
    Finance

    Deckers Brands Reports Third Quarter Fiscal Year 2026 Financial Results

    Third Quarter FY 2026 Revenue Increased 7% to a Record $1.96 Billion Third Quarter FY 2026 Diluted EPS Increased 11% to a Record $3.33 FY 2026 HOKA Revenue Guidance Raised to Mid-teens Percent Increase FY 2026 UGG Revenue Guidance Raised to Mid-single-digits Percent Increase FY 2026 Diluted EPS Guidance Raised to Range of $6.80-$6.85 FY 2026 Share Repurchase Expected to Exceed $1.0 Billion Deckers Brands (NYSE:DECK), a global leader in designing, marketing, and distributing innovative footwear, apparel, and accessories, today announced financial results for the third fiscal quarter ended December 31, 2025. The Company also provided an update to its financial outlook for t

    1/29/26 4:05:00 PM ET
    $DECK
    Shoe Manufacturing
    Consumer Discretionary

    $BCDA
    $BIVI
    $CRDF
    $DECK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Super Micro Computer Inc.

    SC 13G - Super Micro Computer, Inc. (0001375365) (Subject)

    11/14/24 12:52:53 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    SEC Form SC 13G filed by BioVie Inc.

    SC 13G - BIOVIE INC. (0001580149) (Subject)

    10/25/24 4:01:25 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care